Skip to main content

Table 1 Analysis of S100A2 protein expression and correlation with clinicopathological parameters

From: Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients

Clinicopathological Test set External validation set
Features N Cytoplasmic Nuclear p N Cytoplasmic Nuclear p
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Normal 129 1.29 (0.99) 1.07 (1.29)   51 2.55 (0.88) 2.64 (1.05)  
OSCC 235 3.04 (1.26) 0.75 (1.03) <0.00011 115 2.72 (1.06) 2.18 (1.13) 0.051
0.022 0.042
Age (Median, 49 years)         
<49 115 2.97 (1.31) 0.75 (1.02) 0.401 17 3.12 (1.17) 2.50 (1.17) 0.051
≥49 120 3.12 (1.20) 0.75 (1.05) 0.862 98 2.70 (1.01) 2.17 (1.12) 0.222
Gender         
Male 184 3.05 (1.26) 0.73 (1.01) 0.651 68 2.74 (1.03) 2.24 (1.10) 0.681
Female 51 3.00 (1.26) 0.80 (1.11) 0.902 47 2.81 (1.06) 2.18 (1.17) 0.732
Differentiation         
WDSCC 115 3.08 (1.27) 0.81 (1.08)   28 2.82 (1.06) 2.54 (1.10)  
MDSCC 113 2.97 (1.27) 0.70 (0.99) 0.461 70 2.86 (0.92) 2.22 (1.08) 0.281
PDSCC 7 3.57 (0.53) 0.57 (0.98) 0.732 17 2.29 (1.36) 1.68 (1.24) 0.062
Clinical stage         
I 3 2.67 (2.31) 0.67 (1.15)   30 2.70 (1.29) 2.32 (1.26)  
II 38 2.79 (1.26) 0.79 (1.17)   21 2.81 (0.75) 2.48 (1.12)  
III 69 3.12 (1.18) 0.65 (0.87) 0.361 21 2.52 (1.03) 1.67 (0.91) 0.601
IV 125 3.09 (1.28) 0.79 (1.08) 0.942 43 2.91 (0.97) 2.29 (1.07) 0.092
Tumor stage         
I 6 2.67 (1.51) 1.17 (1.33)   48 2.77 (1.17) 2.25 (1.18)  
II 69 2.84 (1.26) 0.81 (1.07)   38 2.53 (0.95) 2.04 (1.22)  
III 65 3.20 (1.19) 0.65 (0.89) 0.141 18 3.06 (0.80) 2.28 (0.89) 0.081
IV 95 3.11 (1.28) 0.75 (1.08) 0.712 10 3.30 (0.67) 2.75 (0.72) 0.372
Nodal status         
N0 81 2.86 (1.43) 0.68 (0.99) 0.321 63 2.78 (1.04) 2.35 (1.11) 0.881
N1–4 154 3.14 (1.15) 0.79 (1.06) 0.462 52 2.75 (1.05) 2.06 (1.13) 0.212
Recurrence status 3         
Non-recurrent 82 2.60 (1.39) 0.80 (1.04) <0.011 47 2.60 (0.92) 2.23 (1.14) 0.051
Recurrent 80 3.30 (1.07) 0.89 (1.13) 0.802 55 2.91 (1.11) 2.16 (1.10) 0.792
  1. 1p of Kruskal-Wallis rank sum test on cytoplasmic S100A2 % positivity score; 2p of Kruskal-Wallis rank sum test on nuclear S100A2 % positivity score; 3Only for OSCC cases with follow up information.